Trimel Pharmaceuticals Stock Rating Reaffirmed by RBC Capital (TRL)
Trimel Pharmaceuticals (TSE:TRL)‘s stock had its “outperform” rating restated by equities research analysts at RBC Capital in a research note issued to investors on Monday, Analyst Ratings Net reports.
Shares of Trimel Pharmaceuticals (TSE:TRL) opened at 0.69 on Monday. Trimel Pharmaceuticals has a 1-year low of $0.335 and a 1-year high of $1.87. The stock’s 50-day moving average is $0.48 and its 200-day moving average is $0.67.
Other equities research analysts have also recently issued reports about the stock. Analysts at Paradigm Capital cut their price target on shares of Trimel Pharmaceuticals from C$2.00 to C$1.75 in a research note to investors on Monday, December 23rd. They now have a “buy” rating on the stock.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.